Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Joseph CiccoliniCindy SerdjebiElisa Giovannetti Review Article Open access 23 March 2016 Pages: 1 - 12
Combinational strategies of metformin and chemotherapy in cancers Hui-Hui ZhangXiu-Li Guo Review Article 27 April 2016 Pages: 13 - 26
Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses Jared M. CampbellEmma BatemanMicah D. J. Peters Review Article 03 May 2016 Pages: 27 - 39
A clinical drug–drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib Vikram MalhiDawn ColburnRichard A. Graham Original Article Open access 06 May 2016 Pages: 41 - 49
Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1 Jiao MoMin KangChen Qing Original Article 09 May 2016 Pages: 51 - 61
Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer D. de WitT. C. SchneiderN. P. van Erp Original Article Open access 11 May 2016 Pages: 63 - 71
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors Shivaani KummarAlice ChenJames H. Doroshow Original Article 11 May 2016 Pages: 73 - 81
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma Oliver E. BechterHerlinde DumezPatrick Schöffski Original Article 11 May 2016 Pages: 83 - 90
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma Hironaga SatakeMakoto TaharaAtsushi Ohtsu Original Article Open access 18 May 2016 Pages: 91 - 99
A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I Andréia Cristina de MeloRachele Grazziotin-ReisnerCarlos Gil Ferreira Original Article 20 May 2016 Pages: 101 - 109
Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation Takaya YamashitaNaohito FujishimaNaoto Takahashi Original Article Open access 23 May 2016 Pages: 111 - 118
UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer Chunlei XuXushan TangYong Tang Original Article 24 May 2016 Pages: 119 - 130
Accounting for dropout in xenografted tumour efficacy studies: integrated endpoint analysis, reduced bias and better use of animals Emma C. MartinLeon AaronsJames W. T. Yates Original Article Open access 25 May 2016 Pages: 131 - 141
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study Kezban Nur PilancıSezer SaglamEsra Kaytan-Saglam Original Article 06 June 2016 Pages: 143 - 150
Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency Muhammad Wasif SaifRobert B. Diasio Original Article 08 June 2016 Pages: 151 - 156
Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites Amit MahipalJason KlapmanMokenge P. Malafa Original Article 08 June 2016 Pages: 157 - 165
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials Mehmet Asim BilenAmy PatelAung Naing Original Article 10 June 2016 Pages: 167 - 171
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment Frank BridouxNianhang ChenJean Paul Fermand Original Article 10 June 2016 Pages: 173 - 182
Effect of renal function on pemetrexed-induced haematotoxicity Yosuke AndoTakahiro HayashiShigeki Yamada Original Article Open access 10 June 2016 Pages: 183 - 189
RETRACTED ARTICLE: Atrial natriuretic peptide protects against cisplatin-induced granulocytopenia Takashi NojiriHiroshi HosodaKenji Kangawa Original Article 10 June 2016 Pages: 191 - 197
Effects of first-line chemotherapy on natural killer cells in adult T-cell leukemia–lymphoma and peripheral T-cell lymphoma Michinori OguraTakashi IshidaAtae Utsunomiya Original Article Open access 11 June 2016 Pages: 199 - 207
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours Sebastiaan C. GouloozePeter GalettisJennifer H. Martin Original Article 13 June 2016 Pages: 209 - 216
Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors Ian J. Cohen Letter to the Editor 23 May 2016 Pages: 217 - 218
Reply to Prof Ian J. Cohen Maurizio LucchesiIacopo Sardi Letter to the Editor 23 May 2016 Pages: 219 - 220